001436886 000__ 05437cam\a2200637\i\4500
001436886 001__ 1436886
001436886 003__ OCoLC
001436886 005__ 20230309004118.0
001436886 006__ m\\\\\o\\d\\\\\\\\
001436886 007__ cr\cn\nnnunnun
001436886 008__ 210527s2021\\\\sz\a\\\\o\\\\\001\0\eng\d
001436886 019__ $$a1262685375$$a1264946109
001436886 020__ $$a9783030687489$$q(electronic bk.)
001436886 020__ $$a3030687481$$q(electronic bk.)
001436886 020__ $$a3030687473
001436886 020__ $$a9783030687472
001436886 020__ $$a9783030687496$$q(print)
001436886 020__ $$a303068749X
001436886 020__ $$a9783030687502$$q(print)
001436886 020__ $$a3030687503
001436886 020__ $$z9783030687472
001436886 0247_ $$a10.1007/978-3-030-68748-9$$2doi
001436886 035__ $$aSP(OCoLC)1252918902
001436886 040__ $$aGW5XE$$beng$$erda$$epn$$cGW5XE$$dOCLCO$$dEBLCP$$dOCLCF$$dVT2$$dUKAHL$$dOCLCQ$$dOCLCO$$dCOM$$dOCLCQ
001436886 049__ $$aISEA
001436886 050_4 $$aRC771$$b.L86 2021
001436886 08204 $$a616.2/41$$223
001436886 24500 $$aLung inflammation in health and disease.$$nVolume II /$$cYong-Xiao Wang, editor.
001436886 264_1 $$aCham :$$bSpringer,$$c[2021]
001436886 264_4 $$c©2021
001436886 300__ $$a1 online resource (xvi, 384 pages) :$$billustrations (some color)
001436886 336__ $$atext$$btxt$$2rdacontent
001436886 337__ $$acomputer$$bc$$2rdamedia
001436886 338__ $$aonline resource$$bcr$$2rdacarrier
001436886 347__ $$atext file
001436886 347__ $$bPDF
001436886 4901_ $$aAdvances in experimental medicine and biology,$$x0065-2598 ;$$vvolume 1304
001436886 500__ $$aIncludes index.
001436886 5050_ $$a1. Can GPCRs be targeted to control inflammation in asthma? -- 2. Cellular and molecular processes in pulmonary hypertension -- 3. INFLAMMATORY PATHWAYS IN SARCOIDOSIS -- 4. Innate Immune Responses and Pulmonary Diseases -- 5. Interstitial Lung Disease associated with Connective Tissue Diseases -- 6. Molecular mechanisms of vascular damage during lung injury -- 7. Neurotrophin Regulation and Signaling in Airway Smooth Muscle -- 8. Novel Thoracic MRI approaches for the assessment of pulmonary physiology and inflammation -- 9. Overview on Interactive Role of Inflammation, Reactive Oxygen Species and Calcium signaling in Asthma, COPD and Pulmonary Hypertension -- 10. Protein S-palmitoylation and lung diseases -- 11. Redox role of ROS and inflammation in pulmonary diseases -- 12. Semaphorin3E/PlexinD1 axis in asthma: what we know so far -- 13. Serine protease inhibitors to treat lung inflammatory diseases -- 14. Sex and Gender Differences in Lung Disease -- 15. Sex hormones and lung inflammation -- 16. Synopsis of Clinical Acute Respiratory Distress Syndrome (ARDS).
001436886 506__ $$aAccess limited to authorized users.
001436886 520__ $$aLung diseases are leading causes of death and disability globally, with about 65 million people suffering from COPD, and 334 million from asthma. Each year, tens of millions of people develop and can die from lung infections such as pneumonia and TB. Systemic inflammation may induce and exacerbate local inflammatory diseases in the lungs, and local inflammation can in turn cause systemic inflammation. There is increasing evidence of the coexistence of systemic and local inflammation in patients suffering from asthma, COPD, and other lung diseases, and the co-morbidity of two or more local inflammatory diseases often occurs. For example, rheumatoid arthritis frequently occurs together with, and promotes the development of, pulmonary hypertension. This co-morbidity significantly impacts quality of life, and can result in death for some patients. Current treatment options for lung disease are neither always effective, nor condition-specific; there is a desperate need for novel therapeutics in the field. Additionally, the molecular and physiological significance of most major lung diseases is not well understood, which further impedes development of new treatments, especially in the case of coexistent lung diseases with other inflammatory diseases. Great progress has been made in recent years in many areas of the field, particularly in understanding the molecular geneses, regulatory mechanisms, signalling pathways, and cellular processes within lung disease, as well as basic and clinical technology, drug discovery, diagnoses, treatment options, and predictive prognoses. This is the first text to aggregate these developments. In two comprehensive volumes, experts from all over the world present state-of-the-art advances in the study of lung inflammation in health and disease. Contributing authors cover well-known as well as emerging topics in basic, translational, and clinical research, with the aim of providing researchers, clinicians, professionals, and students with new perspectives and concepts. The editors hope these books will also help to direct future research in lung disease and other inflammatory diseases, and result in the development of novel therapeutics.
001436886 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed May 27, 2021).
001436886 650_0 $$aPneumonia.
001436886 650_6 $$aPneumonie.
001436886 655_0 $$aElectronic books.
001436886 7001_ $$aWang, Yong-Xiao,$$eeditor.
001436886 77608 $$iPrint version: $$z9783030687472
001436886 77608 $$iPrint version: $$z9783030687496
001436886 77608 $$iPrint version: $$z9783030687502
001436886 830_0 $$aAdvances in experimental medicine and biology ;$$vv. 1304.$$x0065-2598
001436886 852__ $$bebk
001436886 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-030-68748-9$$zOnline Access$$91397441.1
001436886 909CO $$ooai:library.usi.edu:1436886$$pGLOBAL_SET
001436886 980__ $$aBIB
001436886 980__ $$aEBOOK
001436886 982__ $$aEbook
001436886 983__ $$aOnline
001436886 994__ $$a92$$bISE